.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.gif)
.jpg)
Efficacy and Safety of Bisphosphonate Therapy in Patients with Osteogenesis Imperfecta
Keywords:
Bisphosphonates (BPs), Children, Osteogenesis Imperfecta (OI), Metabolic ChangesAbstract
Objective: To determine the efficacy and safety of bisphosphonate therapy in patients with osteogenesis imperfecta.
Methods: 36 patients were included in this study, were of either gender with osteogenesis imperfecta (OI type I, II, III & IV). Patients with hypersensitivity to bisphosphonates, with extra-skeletal complications like pulmonary complications and poor tolerability to bisphosphonates were excluded. Informed written consent was taken. Patients were treated as outpatients on day care basis. Patients were subjected to intravenous BPs (alendronate) weight-dependent (0.5 mg-0.1mg/kg) per dose every 12 weeks. Patients were called for a follow up visit at 3rd and 6th month. The clinical evaluation of efficacy and safety was determined in terms of no fracture and no side effects respectively. Findings were recorded on a predesigned proforma and analyzed using SPSS v23.0. This was a descriptive case series study, conducted at the department of orthopedic surgery from Dec 2022 to May 2023.
Results: The mean alkaline phosphate levels were 470.81+465.09 SD prior to BPs therapy and decreased to 226.92+79.35 SD after three months of BPs therapy. The comparison of means before and after BPs therapy showed significant results (p 0.003). Three months following BPs therapy, 17 (56.7%) males and 13 (43.3%) females had effective results (p 0.764) whereas BPs therapy was safe in 20 (57.1%) males and 15 (42.9%) females and only 01 (100.0%) patient showed mild symptoms of abdominal pain (p 0.257).
Conclusion: Bisphosphonates therapy in children with osteogenesis imperfecta (OI) was effective and safe with a significant reduction in alkaline phosphate levels and decrease in the number of fractures post BPs therapy.
References
Marom R, Rabenhorst BM, Morello R. Management of endocrine disease: Osteogenesis imperfecta: An update on clinical features and therapies. Eur J Endocrinol. 2020;183(4):R95-R106.
Marini JC, Cabral WA. Osteogenesis imperfecta. Genetics Bone Biol Skelet Dis. 2018:397-420.
Claeys L, Storoni S, Eekhoff M, Elting M, Wisse L, Pals G, et al. Collagen transport and related pathways in Osteogenesis Imperfecta. Human Genetics. 2021;140(8):1121-41.
Etich J, Rehberg M, Eckes B, Sengle G, Semler O, Zaucke F. Signaling pathways affected by mutations causing osteogenesis imperfecta. Cell Signal. 2020;76:109789.
Fassier FR. Osteogenesis Imperfecta—Who Needs Rodding Surgery? Curr Osteop Rep. 2021;19:264-70.
Vuorimies I, Mäyränpää MK, Valta H, Kröger H, Toiviainen-Salo S, Mäkitie O. Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta. J Clin Endocrinol Metabol. 2017;102(4):1333-9.
Idolazzi L, Fassio A, Viapiana O, Rossini M, Adami G, Bertoldo F, et al. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: data from open-label, not controlled, three-year Italian study. Bone. 2017;103:144-9.
Hegazy A, Kenawey M, Sochett E, Tile L, Cheung AM, Howard AW. Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy. J Pediatr Orthop. 2016;36(7):757-61.
Zhang Y, Hu J, Lin X, Sun L, Yan S, Zhang Q, et al. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study. Front Endocrinol. 2022;13:901925.
Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, Van Dijk ATH, Sakkers RJB, et al. Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: A systematic review. Horm Res Paediatr 2015; 84(1):26-42.
Kumar C, Panigrahi I, Aradhya AS, Meena BL, Khandelwal N. Zoledronate for Osteogenesis imperfecta: Evaluation of safety profile in children. J Paediatric Endocrinol Metab 2016; 29(8):947-52.
Kumar C, Panigrahi I, Aradhya AS, Meena BL, Khandelwal N. Zoledronate for Osteogenesis imperfecta: Evaluation of safety profile in children. J Paediatric Endocrinol Metab 2016; 29(8):947-52.
Al-Agha AE, Hayatalhazmi RS. Osteoporosis treatment with zoledronic acid in paediatric population at a university hospital in Western Saudi Arabia. A 13-year experience. Saudi Med J 2015; 36(11):1312-8.
Segura MJG, Ríos RG, Blanco LA. Experience with the use of bisphosphonates in osteogenesis imperfecta. Rev Mex Ortop Ped 2018; 20(2):80-5.
Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004; 145(5):701-4
Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, et al. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: A 2-year clinical study. Endocr Pract 2018; 24(2):179-88.
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335(14):1016-21.
Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010; 25(3):447-54.
Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;72(12):930-6.
